| Molecule | Cat. No. | Product Name | Art | Host | Structure | Purity | Activity | Size&Price | Add to Cart |
|---|---|---|---|---|---|---|---|---|---|
| RON | Human RON / MSPR Protein, His Tag (MALS verified) | Human | HEK293 | ![]() | MALSSDS-PAGE | $380.00 100ug |
| Englischer Name | Forschungscode | Forschungsphase | Firma | Indikationen | Klinische Studie |
|---|---|---|---|---|---|
| Ningetinib Tosylate | CT-053-PTSA; CT-053 | Phase 2 Clinical | Hec Pharm Co Ltd | Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Intestinal Neoplasms; Leukemia, Myeloid, Acute; Lung Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| Merestinib | 5OGS5K699E; LY-2801653 | Phase 2 Clinical | Eli Lilly And Company | Biliary Tract Neoplasms; Bone metastases; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Colorectal Neoplasms; Gallbladder Neoplasms; Leukemia, Myeloid, Acute; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Microsatellite instability-high cancer; Neoplasm Metastasis; Neoplasms; Pancreatic Neoplasms; Skin Melanoma; Solid tumours | Details |
| Englischer Name | Forschungscode | Forschungsphase | Firma | Frühestes Markenname | Frühestes Genehmigungsland | Früheste Indikation | Früheste Genehmigungsgesellschaft | Früheste Genehmigungsdatum | Indikationen | Klinische Studie |
|---|---|---|---|---|---|---|---|---|---|---|
| Crizotinib | PF-1066; PF-2341066; PF-02341066; PF-002341066 | Approved | Pfizer Inc | 赛可瑞, Xalkori | United States | Carcinoma, Non-Small-Cell Lung | Pf Prism Cv | 2011-08-26 | Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Granuloma, Plasma Cell; Hematologic Neoplasms; Lung Neoplasms; Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Primary Cutaneous Anaplastic Large Cell; Multiple Myeloma; Myofibroma; Neoplasm Metastasis; Neoplasms; Neurilemmoma; Neuroblastoma; Neurofibromatosis 2; Renal Insufficiency; Solid tumours; Ureteral Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uveal melanoma | Details |